Needham Maintains Buy on DocuSign, Raises Price Target to $340
Needham analyst Scott Berg maintains DocuSign (NASDAQ:DOCU) with a Buy and raises the price target from $275 to $340.
DocuSign Earnings Perspective: Return on Capital Employed
According to Benzinga Pro data, during Q1, DocuSign (NASDAQ:DOCU) posted sales of $469.08 million. Earnings were up 56.87%, but DocuSign still reported an overall loss of $10.74 million.
Earnings Scheduled For September 2, 2021
Companies Reporting Before The Bell
• Navios Maritime Holdings (NYSE:NM) is projected to report earnings for its second quarter.
Analyst Ratings For DocuSign
Within the last quarter, DocuSign (NASDAQ:DOCU) has observed the following analyst ratings:
Monday’s Market Minute: Earnings, Crude, And More To Watch
Looks like another busy week for stocks and futures, let’s take a minute to get ahead of what could move markets. But first, with U.S.
Wedbush Maintains Outperform on DocuSign, Raises Price Target to $340
Wedbush analyst Daniel Ives maintains DocuSign (NASDAQ:DOCU) with a Outperform and raises the price target from $290 to $340.
Cathie Wood’s ARK Invest Posts Fund Sales For Thursday, Aug. 19, 2021: RHHBY, SRPT, PSTI, MCRB, NSTG, DOCU, SQ, XONE
Roche (RHHBY) - 177,900 Shares
Sarepta Therapeutics (SRPT) - 17,408
Pluristem Therapeutics (PSTI) - 7,224
Seres Therapeutics (MCRB) - 10,974
NanoString Technologies (NSTG) - 47,361
DocuSign (DOCU) - 51,743
Square
Cathie Wood’s ARK Invest Posts Fund Sales For Wednesday, Aug. 18, 2021: TXG, SRPT, RHHBY, REGN, PSTI, NVS, MCRB, SQ, DOCU, PRLB, NTDOY, NSTG, XONE, BIDU, SHOP
10x Genomics (TXG) - 48,490
Sarepta Therapeutics (SRPT) - 73,604
Roche (RHHBY) - 140,600
Regeneron Pharmaceuticals (REGN) - 19,393
Pluristem Therapeutics (PSTI) - 9,907
Novartis (NVS) - 52,621
Seres Therapeutics
Palantir, Pfizer, Square, Genius Sports, Docusign — Stocks Cathie Wood’s Ark Bought Or Sold On Wednesday
Cathie Wood-led Ark Invest on Wednesday further increased her bets on Palantir Technologies Inc (NYSE: PLTR) on a day shares of the Peter Thiel-co-founded data analytics company extended gains.